Passive treatment system

Vor Bio Reports Second Quarter 2023 Financial Results and Provides Company Update

Retrieved on: 
Thursday, August 10, 2023
Research and development, European Hematology Association, Bone marrow, Clinical trial, Passive treatment system, G&A, Toxicity, HCT, Editas Medicine, Trial of the century, Acute myeloid leukemia, Health, U.S. FDA, CAR, AML, CD33, Patient, CGMP, Administration, Engineering, HSC, R, FDA, General Administration of Press and Publication, Pharmaceutical industry, Nursing, Medical device, Dentistry, Vaccine, Fine chemical, Gemtuzumab ozogamicin, IND

VCAR33ALLO IND cleared by U.S. FDA; Rapidly activating sites toward study initiation

Key Points: 
  • VCAR33ALLO IND cleared by U.S. FDA; Rapidly activating sites toward study initiation
    CAMBRIDGE, Mass., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today reported financial results for the three-month period ended June 30, 2023, and provided a business update.
  • Research & Development (R&D) Expenses: R&D expenses for the second quarter of 2023 were $23.9 million, compared to $15.3 million for the second quarter of 2022.
  • General & Administrative (G&A) Expenses: G&A expenses for the second quarter of 2023 were $8.3 million, compared to $6.5 million for the second quarter of 2022.
  • Net Loss: Net loss for the second quarter of 2023 was $30.0 million, compared to $21.7 million for the second quarter of 2022.

Vor Bio Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Company Update

Retrieved on: 
Thursday, March 23, 2023
Haematopoiesis, GMP, Research and development, Siddhartha Mukherjee, Bone marrow, Clinical trial, Passive treatment system, Coronavirus Scientific Advisory Board, Cmax, Doctor of Philosophy, HSCT, Trial of the century, Acute myeloid leukemia, MRD, CAR, AML, Good manufacturing practice, CD33, Patient, Investment, CGMP, Transplant, Administration, Blood, AUC, Biology, TANDEM, HSC, R, Services General Administration and Coordination Department, Government of Sindh, IND, Acute promyelocytic leukemia, Satellite navigation device, Nursing, Vaccine, Dentistry, Cryptocurrency, G&A, MD, Gemtuzumab ozogamicin

In December 2022, Vor Bio announced the pricing of an underwritten offering and a private placement, with combined gross proceeds of approximately $115.8 million.

Key Points: 
  • In December 2022, Vor Bio announced the pricing of an underwritten offering and a private placement, with combined gross proceeds of approximately $115.8 million.
  • The Company intends to evaluate VCAR33ALLO in combination with trem-cel as a Treatment System, aiming at prolonged remissions or cures following transplant.
  • General & Administrative (G&A) Expenses: G&A expenses for the fourth quarter of 2022 were $7.7 million, compared to $5.6 million for the fourth quarter of 2021, and for the year ended December 31, 2022, were $28.9 million, compared to $21.5 million for the year ended December 31, 2021.
  • Net Loss: Net loss for the fourth quarter of 2022 was $23.9 million, compared to $18.3 million for the fourth quarter of 2021, and for the year ended December 31, 2022, was $92.1 million, compared to $68.9 million for the year ended December 31, 2021.

First AML Patient Transplanted with Vor Bio’s Trem-cel Demonstrated Durable Engraftment through Multiple Mylotarg™ Cycles at Initial Dose Level

Retrieved on: 
Thursday, February 16, 2023
AML, AUC, CD33, Cmax, Transplant, Aes, Haematopoiesis, Passive treatment system, MRD, Bone marrow, Patient, AE, Vomiting, Memorial Sloan Kettering Cancer Center, Acute promyelocytic leukemia, Acute myeloid leukemia, Learning, IND, MD, Pharmaceutical industry, Gemtuzumab ozogamicin

In the first patient, trem-cel maintained hematopoiesis through three cycles of Mylotarg (gemtuzumab ozogamicin), which was well-tolerated at the initial dose level of 0.5 mg/m2.

Key Points: 
  • In the first patient, trem-cel maintained hematopoiesis through three cycles of Mylotarg (gemtuzumab ozogamicin), which was well-tolerated at the initial dose level of 0.5 mg/m2.
  • A second patient has successfully received a trem-cel transplant and engrafted normally.
  • “We are also encouraged that a second patient successfully received a trem-cel transplant and look forward to learning more as we treat additional patients and dose escalate Mylotarg.
  • The company is moving forward with dose escalation of Mylotarg per the 3+3 dose escalation schema in the protocol.

IOF Announces First International Orthodontic Symposium

Retrieved on: 
Thursday, May 12, 2022
People, World Federation of Orthodontists, Sichuan University, The Forsyth Institute, School, Center, University, Pediatric dentistry, Speech, Patient satisfaction, West Virginia University, Shenzhen NORCO Intelligent Technology, Research, Dentistry, Passive treatment system, Inauguration, Organization, World government, Capital University of Medical Sciences, Department, Treatment, Hospital, Archives of Oral Biology, Eric, Failure, Health, Solution, Learning, Peking University School of Transnational Law, Medical school, Institute, Digital technology, Shanghai Jiao Tong University School of Medicine, IOF, Acceleration, Education, Patient, Dental school, Ohio State University, Technology, Transformation, Industry, Future, University of Zurich, Diagnosis, Management, Pharmaceutical industry, Orthodontics, Orthodontics

The Symposium Will Unveil the Future of Orthodontics for the Next Decade

Key Points: 
  • Hong Kong, China--(Newsfile Corp. - May 12, 2022) - The 1st IOF International Orthodontic Symposium & Inaugural Meeting will be held from June,3rd ~ 5th, 2022.
  • IOF (International Orthodontics Foundation) is an international academic organization in orthodontics and related fields.
  • IOF (International Orthodontics Foundation) is an international academic organization in orthodontics and related fields.
  • Additionally, the IOF will be officially inaugurated during the symposium and the first round of applications for the IOF Research Grants will be launched.